Acute Haemodynamic Study of TPN171H in Patients With Pulmonary Arterial Hypertension
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose
TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial
hypertension.The trial is expected to include 60 patients, divided into 6 groups, according
to 1:1:1:1:1:1 into the placebo group and the test drugs 2.5mg, 5mg, 10mg group, tadalafil
tablets 20mg, 40mg group, each group 10 cases.
Phase:
Phase 2
Details
Lead Sponsor:
Vigonvita Life Sciences
Collaborator:
Shanghai Institute of Materia Medica, Chinese Academy of Sciences